Nuveen Asset Management LLC Boosts Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Nuveen Asset Management LLC lifted its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 49.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 419,190 shares of the biotechnology company's stock after buying an additional 138,176 shares during the period. Nuveen Asset Management LLC owned about 0.66% of Blueprint Medicines worth $36,562,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of BPMC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Blueprint Medicines by 1.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,855 shares of the biotechnology company's stock worth $3,736,000 after acquiring an additional 612 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in Blueprint Medicines by 30.8% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 648,660 shares of the biotechnology company's stock worth $56,576,000 after purchasing an additional 152,573 shares in the last quarter. Gotham Asset Management LLC bought a new position in Blueprint Medicines in the 4th quarter valued at approximately $309,000. Graham Capital Management L.P. boosted its position in Blueprint Medicines by 48.8% in the fourth quarter. Graham Capital Management L.P. now owns 25,260 shares of the biotechnology company's stock valued at $2,203,000 after buying an additional 8,283 shares in the last quarter. Finally, Granahan Investment Management LLC grew its stake in shares of Blueprint Medicines by 8.2% during the fourth quarter. Granahan Investment Management LLC now owns 141,890 shares of the biotechnology company's stock worth $12,376,000 after buying an additional 10,744 shares during the last quarter.

Blueprint Medicines Stock Up 1.2%

Shares of Blueprint Medicines stock traded up $1.16 during trading on Monday, reaching $101.50. 353,347 shares of the company traded hands, compared to its average volume of 781,410. The firm has a market capitalization of $6.56 billion, a PE ratio of -93.98 and a beta of 0.83. Blueprint Medicines Co. has a 1-year low of $73.04 and a 1-year high of $121.90. The company has a 50 day moving average price of $90.77 and a 200-day moving average price of $94.58. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The company had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. During the same period last year, the company earned $1.40 EPS. Blueprint Medicines's revenue for the quarter was up 55.5% compared to the same quarter last year. As a group, equities research analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on BPMC shares. Scotiabank assumed coverage on Blueprint Medicines in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 price target for the company. Needham & Company LLC dropped their target price on Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Jefferies Financial Group began coverage on Blueprint Medicines in a report on Monday, March 17th. They set a "buy" rating and a $135.00 price target on the stock. Wall Street Zen upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Finally, Wedbush reiterated an "outperform" rating and set a $128.00 target price on shares of Blueprint Medicines in a research report on Thursday, May 1st. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Blueprint Medicines currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.56.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. The trade was a 3.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ariel Hurley sold 2,752 shares of the company's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $103.13, for a total transaction of $283,813.76. Following the transaction, the insider now owns 16,944 shares in the company, valued at approximately $1,747,434.72. The trade was a 13.97% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,777 shares of company stock valued at $1,256,490. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.